Annual report [Section 13 and 15(d), not S-K Item 405]

STOCKHOLDERS' EQUITY (Details)

v3.25.0.1
STOCKHOLDERS' EQUITY (Details)
 1 Months Ended 12 Months Ended
Jul. 21, 2024
USD ($)
D
$ / shares
shares
Sep. 08, 2023
USD ($)
$ / shares
shares
Oct. 25, 2022
USD ($)
$ / shares
shares
Jan. 31, 2024
USD ($)
$ / shares
shares
Dec. 31, 2024
USD ($)
$ / shares
shares
Dec. 31, 2023
USD ($)
$ / shares
shares
Oct. 31, 2022
shares
STOCKHOLDERS' EQUITY              
Warrants issued to purchase shares         24,582,748    
Proceeds from exercise of warrants | $         $ 61,410,815 $ 789,642  
Warrant liability | $         1,718,000 16,120,898  
Exercise of warrants into common shares | $         $ 2,298,143 $ 2,467,222  
Number of warrants exercised         547,177    
Common stock par value | $ / shares         $ 0.00001 $ 0.00001  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period         1,667    
September 2023 Private Placement              
STOCKHOLDERS' EQUITY              
Gross proceeds | $   $ 24,500,000          
Net proceeds | $   $ 22,200,000          
October 2022 Public Offering and Private Placement              
STOCKHOLDERS' EQUITY              
Warrants issued to purchase shares     3,275,153        
Gross proceeds | $     $ 10,700,000        
Proceeds from exercise of warrants | $         $ 1,100,000    
Exercise price of warrants (in dollars per share) | $ / shares     $ 2.085        
Estimated offering expenses | $     $ 9,600,000        
Common Stock              
STOCKHOLDERS' EQUITY              
Conversion of preferred shares into common shares (in shares)           9,947,684  
Exercise of warrants into common shares (in shares)         547,177 1,197,622  
Exercise of warrants into common shares | $         $ 5 $ 12  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period         767    
Common Stock | October 2022 Public Offering and Private Placement              
STOCKHOLDERS' EQUITY              
Warrants issued to purchase shares     1,875,945        
Exercise price of warrants (in dollars per share) | $ / shares     $ 1.96        
Common Stock | September 2023 Private Placement              
STOCKHOLDERS' EQUITY              
Convertible preferred shares issued   9,947,684          
Common stock par value | $ / shares   $ 1.82          
Series E Warrants | September 2023 Private Placement              
STOCKHOLDERS' EQUITY              
Share price | $ / shares   $ 20,000          
Series E-1 preferred stock | September 2023 Private Placement              
STOCKHOLDERS' EQUITY              
Shares issued   1,225          
Conversion price per share | $ / shares   $ 1.82          
Convertible preferred shares issued   13,461,538          
Gross proceeds from stockholders' equity | $   $ 17,820,000          
Series E-2 Preferred Stock              
STOCKHOLDERS' EQUITY              
Fair value of the warrants allocated to preferred stock | $           $ 17,820,000  
Preferred stock, share outstanding         35.6 319.76  
Series E-2 Preferred Stock | September 2023 Private Placement              
STOCKHOLDERS' EQUITY              
Number of shares converted   905.24          
Conversion of preferred shares into common shares (in shares)         284.16    
Preferred stock, share outstanding         35.6 319.76  
Series E-2 Preferred Stock | Common Stock              
STOCKHOLDERS' EQUITY              
Conversion of preferred shares into common shares (in shares)         3,122,637    
Series E-2 Preferred Stock | Common Stock | September 2023 Private Placement              
STOCKHOLDERS' EQUITY              
Conversion of preferred shares into common shares (in shares)         3,122,637    
Series E-3 preferred stock | September 2023 Private Placement              
STOCKHOLDERS' EQUITY              
Conversion price per share | $ / shares   $ 3.185   $ 3.185      
Convertible preferred shares issued   13,846,154          
Series E-3 preferred stock | Common Stock              
STOCKHOLDERS' EQUITY              
Conversion of preferred shares into common shares (in shares)         13,846,141    
Series E-4 preferred stock              
STOCKHOLDERS' EQUITY              
Fair value of the warrants allocated to preferred stock | $ $ 15,900,000       $ (15,914,632)    
Series E-4 preferred stock | September 2023 Private Placement              
STOCKHOLDERS' EQUITY              
Conversion price per share | $ / shares   $ 4.7775          
Convertible preferred shares issued   7,179,487          
Series E-4 preferred stock | Common Stock              
STOCKHOLDERS' EQUITY              
Conversion of preferred shares into common shares (in shares)         6,739,919    
Tranche A and B Warrants | September 2023 Private Placement              
STOCKHOLDERS' EQUITY              
Gross proceeds from stockholders' equity | $   $ 4,800,000          
Common Stock | October 2022 Public Offering and Private Placement              
STOCKHOLDERS' EQUITY              
Conversion of preferred shares into common shares (in shares)           0  
July 2024 Warrants              
STOCKHOLDERS' EQUITY              
Warrant liability | $ 12,000,000       $ 1,200,000    
Fair value of warrants | $ 17,000,000            
Common warrants | October 2022 Public Offering and Private Placement              
STOCKHOLDERS' EQUITY              
Conversion of preferred shares into common shares (in shares)         1,079,132    
Prefunded Warrant | October 2022 Public Offering and Private Placement              
STOCKHOLDERS' EQUITY              
Warrants issued to purchase shares     1,875,945        
pre-funded warrants         1,079,132    
Tranche A Warrants | September 2023 Private Placement              
STOCKHOLDERS' EQUITY              
Warrants term       10 days      
Tranche A Warrants | Series E-3 preferred stock | September 2023 Private Placement              
STOCKHOLDERS' EQUITY              
Proceeds from exercise of warrants | $       $ 44,100,000      
Exercise of warrants into common shares (in shares)       2,205      
Exercise of warrants into common shares | $       $ 42,800,000      
2023 Tranche A Preferred Warrants | Series E-3 preferred stock | September 2023 Private Placement              
STOCKHOLDERS' EQUITY              
Warrants issued to purchase shares   2,205          
Proceeds from exercise of warrants | $   $ 44,100,000          
Number of days | $   10          
2023 Tranche B Preferred Warrants              
STOCKHOLDERS' EQUITY              
Warrants issued to purchase shares         439,560    
Exercise price of warrants (in dollars per share) | $ / shares         $ 4.7775    
Exercise or Settlement of warrants | $ 2,600,000            
Value in excess of the net proceeds and fair value | $ $ 7,700,000            
2023 Tranche B Preferred Warrants | Series E-4 preferred stock              
STOCKHOLDERS' EQUITY              
Warrants issued to purchase shares 1,610            
Preferred stock, par value (in dollars per share) | $ / shares $ 0.00001            
Number of shares issuable upon conversion of preferred stock 6,739,919            
Conversion price per share | $ / shares $ 2.52            
Proceeds from exercise of warrants | $ $ 19,400,000            
Net proceeds from warrant exercises | $ $ 17,500,000            
2023 Tranche B Preferred Warrants | Series E-4 preferred stock | September 2023 Private Placement              
STOCKHOLDERS' EQUITY              
Warrants issued to purchase shares   1,715          
Proceeds from exercise of warrants | $   $ 34,300,000          
Number of days | $   10          
2022 Pre-Funded Common Warrants              
STOCKHOLDERS' EQUITY              
Warrants issued to purchase shares             1,875,941
2022 Pre-Funded Common Warrants | October 2022 Public Offering and Private Placement              
STOCKHOLDERS' EQUITY              
Exercise price of warrants (in dollars per share) | $ / shares     $ 0.00001        
Purchase price | $ / shares     $ 2.08499        
2022 Common Warrants              
STOCKHOLDERS' EQUITY              
Warrants issued to purchase shares         4,201,044    
Exercise price of warrants (in dollars per share) | $ / shares         $ 1.96    
2024 Tranche A Warrants              
STOCKHOLDERS' EQUITY              
Warrants issued to purchase shares         6,739,918    
Exercise price of warrants (in dollars per share) | $ / shares $ 2.52       $ 2.52    
Number of Days following the Announcement of Prescription Drug Use Fee Act Goal By FDA | D 10            
2024 Tranche B Warrants              
STOCKHOLDERS' EQUITY              
Warrants issued to purchase shares         8,214,278    
Exercise price of warrants (in dollars per share) | $ / shares $ 4       $ 4    
Number of days following the date of the Company's public announcement of its receipt of written approval from the FDA | D 10            
2024 Tranche C Warrants              
STOCKHOLDERS' EQUITY              
Warrants issued to purchase shares         4,267,152    
Exercise price of warrants (in dollars per share) | $ / shares $ 5.5       $ 5.5    
Number of days following the announcement of quarterly gross revenue from sales of iopofosine I 131. | D 10            
Threshold amount of quarterly gross revenues trigger for expiry of warrants | $ $ 10,000,000